80 related articles for article (PubMed ID: 38550593)
1. Immune cell infiltration and prognostic index in cervical cancer: insights from metabolism-related differential genes.
Ma B; Ren C; Yin Y; Zhao S; Li J; Yang H
Front Immunol; 2024; 15():1411132. PubMed ID: 38840928
[TBL] [Abstract][Full Text] [Related]
2. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
[TBL] [Abstract][Full Text] [Related]
3. Stage-specificity of STING activation in intrahepatic cholangiocarcinoma determines the efficacy of its agonism.
Luo S; Li S; Liu C; Yu D; Sun L; Zhang S; Zhao N; Zhang M; Nie J; Zhao Y; Li C; Zhang Y; Zhang Q; Meng H; Li X; Shi J; Zheng T
Cancer Lett; 2024 May; 594():216992. PubMed ID: 38797231
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice.
Du WY; Masuda H; Nagaoka K; Yasuda T; Kuge K; Seto Y; Kakimi K; Nomura S
Gastric Cancer; 2024 May; ():. PubMed ID: 38805119
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors.
Li J; Deng Z; Liu Y; Jin J; Xie C; Gan J
Discov Oncol; 2024 Jun; 15(1):216. PubMed ID: 38852126
[TBL] [Abstract][Full Text] [Related]
6. Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy.
Li Z; Zhang Q; Li Z; Ren L; Pan D; Gong Q; Gu Z; Cai H; Luo K
Acta Pharm Sin B; 2024 May; 14(5):2194-2209. PubMed ID: 38799622
[TBL] [Abstract][Full Text] [Related]
7. A next-generation STING agonist MSA-2: From mechanism to application.
Yang J; Luo Z; Ma J; Wang Y; Cheng N
J Control Release; 2024 Jun; 371():273-287. PubMed ID: 38789087
[TBL] [Abstract][Full Text] [Related]
8. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.
Wilson J; Kimmel B; Arora K; Chada N; Bharti V; Kwiatkowski A; Finklestein J; Hanna A; Arner E; Sheehy T; Pastora L; Yang J; Pagendarm H; Stone P; Taylor B; Hubert L; Gibson-Corley K; May J; McLean J; Rathmell J; Richmond A; Rathmell W; Balko J; Fingleton B; Hargrove-Wiley E
Res Sq; 2024 May; ():. PubMed ID: 38766114
[TBL] [Abstract][Full Text] [Related]
9. Delivery of mRNA Encoding Interleukin-12 and a Stimulator of Interferon Genes Agonist Potentiates Antitumor Efficacy through Reversing T Cell Exhaustion.
Wang B; Tang M; Chen Q; Ho W; Teng Y; Xiong X; Jia Z; Li X; Xu X; Zhang XQ
ACS Nano; 2024 Jun; ():. PubMed ID: 38832815
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline Targets Multiple Pathways to Inhibit PRL Secretion and Increases Stromal Fibrosis.
Zhang D; Hugo W; Bergsneider M; Wang MB; Kim W; Han K; Vinters HV; Heaney AP
Eur J Endocrinol; 2024 May; ():. PubMed ID: 38781434
[TBL] [Abstract][Full Text] [Related]
11. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
12. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
13. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
14. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract][Full Text] [Related]
15. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
Yang KS; Xu CQ; Lv J
Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
